Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was incorporated in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma LLC.
Pomerantz LLP is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or the “Company”) (NASDAQ: EIDX). The investigation concerns whether Eidos and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of Eidos and are interested in obtaining additional information regarding this investigation, you are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]